^
    8d
    Development of a Synthetic Secondary Standard for the Quantification of p210 BCR-ABL1 Standardized to the International Scale (IS) (AMP 2024)
    A linear relationship was found between reported and assigned values for all levels of the reference standards when tested across 3 different BCR-ABL RT-qPCR assays, enabling the calculation of an assay-specific CF to allow harmonized reporting on the International Scale (%IS). The BCR-ABL p210 Panel was validated for accuracy, precision, robustness, and traceability, and can be used as a WHO traceable reference standard to create assay-specific CF to enable standardized reporting on the International Scale (%IS).
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    BCR-ABL1 mutation
    |
    ipsogen BCR-ABL1 mbcr Kit
    2years
    Analytical Validation of the BCR-ABL p190 Transcripts Using GeneXpert Dx System (AMP 2022)
    The Cepheid Xpert p190 RUO assay demonstrated excellent laboratory performance on both clinical and contrived materials as compared to the laboratory test of record. The simplicity of the assay also allows for decreased turnaround, less hands-on time, and fewer required technical skills which may enable increased laboratory efficiencies over conventional methods.
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    BCR-ABL1 fusion
    |
    Xpert® BCR-ABL Ultra • ipsogen BCR-ABL1 mbcr Kit
    3years
    [VIRTUAL] Method Comparison between Two Commercially Available BCR-ABL1 Quantitative Kits (AMP 2021)
    The 2 kits were highly correlated over the full range of values obtained. Some bias was observed, arising from differences in quantifying e13a2. Qualitative agreement of detection was high, but interpretation was complicated by replicate-discrepant BCR-ABL1 results
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    BCR-ABL1 fusion
    |
    Quantidex qPCR BCR-ABL IS Kit • ipsogen BCR-ABL1 mbcr Kit